Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

The FDA approved Lynparza for ovarian cancer after a Phase 2 trial of 265 patients.

"Lynparza’s efficacy was examined in a study where 137 participants with gBRCAm-associated ovarian cancer received the drug. The study was designed to measure objective response rate (ORR), or the percentage of participants who experienced partial shrinkage or complete disappearance of the tumor. Results showed 34 percent of participants experienced ORR for an average of 7.9 months."

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm?version=meter+at+2&module=meter-Links&pgtype=article&contentId=&mediaId=&referrer=http%3A%2F%2Finvestorshub.advfn.com%2Fboards%2Fread_msg.aspx%3Fmessage_id%3D119556801&priority=true&action=click&contentCollection=meter-links-click

I'm looking forward to seeing the protocol for K-OC. If the objective response rate is the primary endpoint, then the trial shouldn't take long.

K is 10 years away and by then it's a dinosaur